Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Adherium Ltd. ( (AU:ADR) ) is now available.
Adherium Ltd., the ASX-listed healthcare technology company trading under ticker ADR, develops medical devices and digital adherence solutions aimed at improving monitoring and management of chronic conditions such as respiratory diseases. Its products are targeted at patients, clinicians, and healthcare systems seeking better data-driven oversight of treatment compliance.
The company has updated investors that it will extend the closing date of its retail component of an accelerated non-renounceable entitlement offer, moving the deadline from 5 March 2026 to 12 March 2026 at 5:00 p.m. AEDT. The extension gives retail shareholders additional time to participate in the proposed issue of securities, potentially supporting stronger take-up of the offer and providing Adherium with greater flexibility in securing the desired capital for its ongoing operations and growth plans.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Ltd. is an Australia-listed company on the ASX under the code ADR. The firm operates in the healthcare technology sector, focusing on medical devices and digital solutions that support patient adherence and monitoring, with a particular emphasis on respiratory and chronic disease management markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.97M
For a thorough assessment of ADR stock, go to TipRanks’ Stock Analysis page.